Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P21912

UPID:
SDHB_HUMAN

ALTERNATIVE NAMES:
Iron-sulfur subunit of complex II

ALTERNATIVE UPACC:
P21912; B2R545; Q0QEY7; Q9NQ12

BACKGROUND:
The mitochondrial Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, known alternatively as the Iron-sulfur subunit of complex II, is crucial for electron transfer within the mitochondrial respiratory chain. It specifically mediates the conversion of succinate to ubiquinone (coenzyme Q), a key step in the process of cellular respiration.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of the Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial could open doors to potential therapeutic strategies. Its involvement in diseases such as Pheochromocytoma, Paragangliomas 4, and Mitochondrial complex II deficiency highlights its significance in human health and disease.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.